Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Gobin, Bérengère ^a,b   Moriceau, Gatien ^a,b   Ory, Benjamin ^a,b,c   Charrier, Céline ^a,b,c   Brion, Régis ^a,b,c,d   Blanchard, Frederic ^a,b,c   Redini, Françoise ^a,b,c,d   Heymann, Dominique ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Equipe LIGUE Nationale Contre le Cancer 2012   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CASPASES; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOCOMPETENCE; MALE; MICE; MICE, INBRED C57BL; MITOSIS; OSTEOSARCOMA; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RATS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84897147716     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090795     Document Type: Article

References (45)

1. Heymann D and Redini F (2011) Bone sarcomas: pathogenesis and new therapeutic approaches. IBMS BoneKey 8: 402-414.
2. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC (1976) Chemotherapy, en bloc resection, and prosthetic bone replacement in treatment of osteogenicsarcoma. Cancer 37: 1-11.
3. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, et al (2012) A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 704872.
4. Ando K, Heymann MF, Stresing V, Mori K, Rédini F, et al (2013) Current Therapeutic Strategies and Novel Approaches in Osteosarcoma. Cancers 5: 591-616.
5. Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetino FH, et al (2012) Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer 118: 750-760.
6. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, et al (2012) Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 30: 78-84.
7. Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, et al (2010) Zoledronic acid potentiates mTOR inhibition and abolishes the resistance resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res 70: 10329-10339.
8. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, et al. (2010) NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-540.
9. Hingorani P, Zhang W, Gorlick R, Kolb EA (2009) Inhibition of src phosphorylation alters metastatic potential of osteosarco main vitro but not in vivo. Clin Cancer Res 15: 3416-3422.
10. Savage DG, Antman KH (2002) Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346: 683-693. (Pubitemid 34815874)
11. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004. (Pubitemid 36302244)
12. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, et al (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39: 2006-2011. (Pubitemid 37297756)
13. El Hajj Dib I, Gallet M, Mentaverri R, Sévenet N, Brazier M, et al (2006) Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 551: 27-33. (Pubitemid 44648069)
14. O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, et al (2007) Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal-cell dependent mechanisms. J Bone Miner Res 22: 1679-1689. (Pubitemid 351235134)
15. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, et al (2007) Inhibition of platelet-derived growth factor receptor b by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 40: 355-366. (Pubitemid 46802187)
16. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino ACW (2010) Dysregulation of bone remodeling by imatinib mesylate. Blood 115: 766-774.
17. Klein B, Pals S, Masse R, Lafuma J, Morin M, et al (1977) Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride. Int J Cancer 20: 112-119. (Pubitemid 8139751)
18. Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T (2002) Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett 188: 213-219. (Pubitemid 35292347)
19. Joliat MJ, Umeda S, Lyons BL, Lynes MA, Shultz LD (2002) Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. In Vivo 16: 223-228.
20. Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, et al (2007) Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the vicious cycle between tumour cell proliferation and bone resorption. Cancer Res 67: 7308-7318. (Pubitemid 47206560)
21. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets. Blood 110: 4055-4063. (Pubitemid 350248462)
22. Winger JA, Hantschel O, Superti-Furga G, Kuriyan J (2009) The structure of the leukaemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol 9:7.
23. Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, et al (2009) The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian a-carbonic anhydrase isoforms. Bioorg Med Chem Lett 19: 4102-4106.
24. Deschaseaux F, Sensébé L, Heymann D (2009) Mechanisms of bone repair and regeneration. Trends Mol Med 15: 417-429.
25. Mohseny AB, Hogendoorn PC (2011) Concise review: mesenchymal tumours: when stem cells go mad. Stem Cells 29: 397-403.
26. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, et al (2007) Mesenchymal stem cell features of Ewing tumours. Cancer Cell 11: 421-429. (Pubitemid 46680428)
27. McGary EC, Weber K, Mills L, Doucet M, Lewis V, et al (2002) Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591. (Pubitemid 35340737)
28. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, et al (2008). Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 112: 2119-2129. (Pubitemid 351628620)
29. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, et al (2008) A phase II study of imatinib mesylate in children with refractory or relapsed solid tumours: a Children's Oncology Group study. Pediatr Blood Cancer 50: 254-258.
30. Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, et al (2013) Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes to Cells 18: 110-122.
31. Nakano T, Tani M, Ishibashi Y, Kimura K, Park YB, et al (2003) Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis 20: 665-674. (Pubitemid 37463904)
32. Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ, et al (2012) Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 1: e34.
33. Zhang Y, Tang YJ, Man Y, Pan F, Li ZH, et al (2013) Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis. Int J Immunopathol Pharmacol 26: 179-188.
34. Han J, Tian R, Yong B, Luo C, Tan P, et al (2013) Gas6/Axl mediates tumour cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. Biochem Biophys Res Commun 435: 493-500.
35. Miiji LN, Petrilli AS, Di Cesare S, Odashiro AN, Burnier MN Jr, et al (2011) Ckit expression in human osteosarcoma and in vitro assays. Int J Clin Exp Pathol 4: 775-4781.
36. Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, et al (2010) De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathol 57: 836-850.
37. Mstuo K, Otaki N (2012) Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adh Migr 6: 148-156.
38. Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, et al (2013) Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer 109: 2142-2154.
39. Truitt L, Freywald A (2011) Dancing with the dead: Eph receptors and their kinase-null partners. Biochem Cell Biol 89: 115-129.
40. Lee JA, Ko Y, Kim DH, Lim JS, Kong CB, et al (2012) Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma? Cancer Res Treat 44: 202-209.
41. Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, et al (2013) IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 13: 245.
42. Angers S, Moon RT (2009) Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 10: 468-477.
43. Macheda ML, Stacker SA (2008) Importance of Wnt signaling in the tumour stroma microenvironment. Curr Cancer Drug Targets 8: 454-465.
44. McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, et al (2011) The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther 11: 1223-1232.
45. Lavenus S, Berreur M, Trichet V, Pilet P, Louarn G, et al (2011) Adhesion and osteogenic differentiation of human mesenchymal stem cells on titanium nanopores. Eur Cell Mater 22: 84-96.